Controlled-release morphine in cancer pain. Is a loading dose required when the formulation is changed?

Area of Science:

• Oncology
• Pharmacology
• Pain Management

Background:

• Patients with advanced cancer pain often require opioid analgesics.
• Switching between morphine formulations, such as oral aqueous morphine to controlled-release morphine tablets (MST Continus), is common in pain management.
• Optimizing the conversion process is crucial to maintain pain control and minimize adverse effects.

Purpose of the Study:

• To determine if a loading dose of oral aqueous morphine is necessary when converting patients to twice-daily MST Continus.
• To assess the impact of a loading dose on pain intensity, pain relief, and side effects during the conversion process.

Main Methods:

• A randomized, placebo-controlled study involving 19 patients with advanced cancer pain stabilized on 4-hourly oral morphine.
• Patients were converted to MST Continus and randomized to receive either their usual 4-hourly morphine dose or a placebo with the first MST dose.
• Pain intensity, pain relief, side effects, and pharmacokinetic parameters were assessed.

Main Results:

• No significant differences were observed between the active loading dose and placebo groups in pain intensity, pain relief, or side effects.
• Pharmacokinetic parameters showed no significant variations between the groups.
• Nursing staff could not distinguish between patients receiving the active loading dose versus placebo, and no breakthrough pain was reported in the placebo group.

Conclusions:

• A loading dose of oral aqueous morphine is not required when converting patients to MST Continus.
• The conversion from 4-hourly oral morphine to twice-daily MST Continus can be safely managed without an additional loading dose.
• This simplifies pain management protocols for advanced cancer patients.